Podcast appearances and mentions of Melissa L Johnson

Immunotherapy in “Hardest Stage” of NSCLC: Putting Recent Advances Into Practice Our host, Robert A. Figlin, MD, FACP, welcomes Melissa L. Johnson, MD, as a guest  

Melissa L. Johnson is a celebrated author renowned for her evocative storytelling and deep exploration of human emotions. Her latest work, "Soul-Deep Beauty," delves into the intricate ways beauty manifests both within and beyond the physical realm, captivating readers with its profound insights. With a background in psychology, Melissa skillfully weaves themes of self-discovery and personal growth into her narratives, making her a beloved figure among readers seeking both entertainment and enlightenment. Her writing not only entertains but also challenges readers to reflect on their own perceptions of beauty and identity. Melissa's unique voice and thoughtful prose continue to earn her a place in the hearts of those who cherish literature that resonates on a soul-deep level. Related Links: AMAZON: Soul-deep Beauty: Fighting for Our True Worth in a World Demanding Flawless WEBSITE: Impossible-Beauty.com

QUOTES FOR REFLECTION “I was given eyes to see societal ‘beauty' in a new way; ‘beauty' was exposed for what it really was. Totally empty and not beautiful at all. “I saw how societal ‘beauty' ran on insecurity and shame. And that it was all on purpose. Making women feel like their face, or body, or skin is ‘wrong' so they'll adhere to a diet or buy a product to ‘fix' themselves. In short, I was awakened to the black hole that is American ‘beauty,' its gravity impacting the minds, the hearts, the souls of so many girls and women.”~Melissa L. Johnson, Soul-Deep Beauty: Fighting for Our True Worth in a World Demanding Flawless “…the promises of the law are conditional, promising life not freely, but to those who fulfill the law; therefore, they leave people's consciences in doubt, for no one fulfills the law. But the promises of the new covenant have no such condition attached. They do not require anything of us; they do not depend on any condition of our worthiness but freely give us forgiveness of sins, grace, righteousness, and everlasting life for Christ's sake.”~Martin Luther (1483-1546), famed religious reformer “…our conscience must be instructed and prepared beforehand, so that when we feel the accusation of the law, the terrors of sin, the horror of death and the wrath of God we may remove these dire sights and fearful ideas from our minds and replace them with the freedom purchased by Christ, the forgiveness of sins, righteousness, life, and the everlasting mercy of God. Although the contrary feeling may be very strong, we must assure ourselves that it will not last long (Isaiah 54:8). But this is very hard to do. Therefore, it is easier to speak of the freedom that Christ purchased for us than it is to believe it.”~Martin Luther in his Galatians Commentary (1535) “Unless this freedom be comprehended, neither Christ nor gospel truth, nor inner peace of soul, can be rightly known.”~John Calvin (1509-1564), Genevan religious reformer “True freedom is to be one's true self, but my true self is made for loving, and loving is self-giving. So in order to be myself, I have to deny myself and give myself. In order, then, to be free, I have to give up my freedom. In order, then, to live, I have to die to my self-centeredness. In order to find myself, I've got to lose it.”~John Stott (1921-2011), English pastor and theologian SERMON PASSAGEGalatians 4:28-5:6 (ESV)Galatians 4 28 Now you, brothers, like Isaac, are children of promise. 29 But just as at that time he who was born according to the flesh persecuted him who was born according to the Spirit, so also it is now. 30 But what does the Scripture say? “Cast out the slave woman and her son, for the son of the slave woman shall not inherit with the son of the free woman.” 31 So, brothers, we are not children of the slave but of the free woman. Galatians 5 1 For freedom Christ has set us free; stand firm therefore, and do not submit again to a yoke of slavery.2 Look: I, Paul, say to you that if you accept circumcision, Christ will be of no advantage to you. 3 I testify again to every man who accepts circumcision that he is obligated to keep the whole law. 4 You are severed from Christ, you who would be justified by the law; you have fallen away from grace. 5 For through the Spirit, by faith, we ourselves eagerly wait for the hopeof righteousness. 6 For in Christ Jesus neither circumcision nor uncircumcision counts for anything, but only faith working through love. 7 You were running well. Who hindered you from obeying the truth? 8 This persuasion is not from him who calls you. 9 A little leaven leavens the whole lump. 10 I have confidence in the Lord that you will take no other view, and the one who is troubling you will bear the penalty, whoever he is. 11 But if I, brothers, still preach circumcision, why am I still being persecuted? In that case the offense of the cross has been removed. 12 I wish those who unsettle you would emasculate themselves! 13 For you were called to freedom, brothers. Only do not use your freedom as an opportunity for the flesh, but through love serve one another. 14 For the whole law is fulfilled in one word: “You shall love your neighbor as yourself.” 15 But if you bite and devour one another, watch out that you are not consumed by one another.

Hey friend, let's ditch diet culture, shame and insecurity as we redefine beauty in Midlife! My guest today is Melissa L. Johnson, a marriage and family therapist, as well as a spiritual director.   Melissa walked through her own challenges with an eating disorder and God has called her to help others not only with eating disorders or disordered eating but to encourage other women to stand boldly as faith fueled women. In a world saturated with diet culture, fake beauty, shame and feelings of unworthiness PLUS the toxic teachings of the cosmetic industry, Melissa encourages you to ditch the world focused shame and insecurity that is thrown at you and lean into what God says about you as His daughter.  As we are beginning a new year with new marketing towards improving yourself the way the world thinks you should, I pray this is encouraging and gives you hope as you listen. You see it all the time: women are purposely being shown unrealistic and unhealthy images online, in commercials, in ads, magazines. This is nothing new but there more and more specific marketing targeted towards those of us in this midlife phase of life. Geared towards us covering up and masking up our true God given beauty and signs of a life lived as we are in this midlife season. I encourage you to lean into your true worth and recognize that you are a beautiful and a treasured possession in God's eyes.  Recognize the lies of the enemy and when you are in the middle of a spiritual battle as it pertains to your looks, your beauty, your skin, your weight, your intelligence and so on. Seek God first for everything and rebuke the lies of the enemy.  Words have power my friend, so as you listen, ask the Lord to show you where you have been falling for lies and take some time to dig into what God says about you.  I pray this is a blessing and encouragement to you today! XO, Michelle Connect with Melissa: www.impossible-beauty.com   ***Join our community, Holistic Health for Christian Women over 40, to be supported and encouraged as you work towards regaining energy and reclaiming your health! **Catch the Treasured Wellness Podcast on https://christianmix106.com/   YouTube  AND https://actsmediagroup.net/radio-free-america-internet-radio/   Related Episodes:  Ep. 217 Treasure your Midlife Wellness Ep. 228 A New Year WITH God Mindset Challenge  

Go online to PeerView.com/YMP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Antibody–drug conjugates (ADCs) are the next frontier in the treatment of lung cancer, addressing unmet needs, expanding options, and providing new hope of improved outcomes for diverse populations of patients. Extensive efforts are ongoing to evaluate and bring new ADCs to clinical practice, including those targeting HER3 and TROP2. Initial studies have already yielded promising new data, and many other clinical trials are actively evaluating ADCs targeting HER3, TROP2, and others in different patient populations and treatment settings. This educational activity, based on a recent live symposium, provides an expert-led exploration of the fast-paced evolution of the role and impact of ADC-based approaches in lung cancer. Learners can achieve a better understanding of the structure and function of modern ADCs, the rationale for targeting HER3 and TROP2 with ADCs in lung cancer, and the rapidly accumulating evidence base supporting their use in practice. Going beyond the basics, the expert panel also shares in-depth perspectives on where the novel ADCs may fit within the complex lung cancer treatment arsenal, nuances of patient selection, how to best integrate them into treatment plans, and how to recognize and manage unique adverse events associated with different ADCs. Watch this activity to learn how to maximize the potential of these novel ADCs for the benefit of patients with lung cancer. Upon completion of this activity, participants should be better able to: Discuss the clinical importance and biologic rationale for targeting HER3 and TROP2 with novel ADCs in lung cancer; Summarize the characteristics, mechanisms of action, and safety and efficacy profiles of ADCs targeting HER3 and TROP2 in NSCLC; Identify patients with NSCLC who are likely to be appropriate candidates for treatment with novel ADCs targeting HER3 and TROP2; and Implement best practices to effectively and safely integrate novel ADCs, including those targeting HER3 and TROP2, into treatment plans for appropriate patients with NSCLC

Go online to PeerView.com/YMP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Antibody–drug conjugates (ADCs) are the next frontier in the treatment of lung cancer, addressing unmet needs, expanding options, and providing new hope of improved outcomes for diverse populations of patients. Extensive efforts are ongoing to evaluate and bring new ADCs to clinical practice, including those targeting HER3 and TROP2. Initial studies have already yielded promising new data, and many other clinical trials are actively evaluating ADCs targeting HER3, TROP2, and others in different patient populations and treatment settings. This educational activity, based on a recent live symposium, provides an expert-led exploration of the fast-paced evolution of the role and impact of ADC-based approaches in lung cancer. Learners can achieve a better understanding of the structure and function of modern ADCs, the rationale for targeting HER3 and TROP2 with ADCs in lung cancer, and the rapidly accumulating evidence base supporting their use in practice. Going beyond the basics, the expert panel also shares in-depth perspectives on where the novel ADCs may fit within the complex lung cancer treatment arsenal, nuances of patient selection, how to best integrate them into treatment plans, and how to recognize and manage unique adverse events associated with different ADCs. Watch this activity to learn how to maximize the potential of these novel ADCs for the benefit of patients with lung cancer. Upon completion of this activity, participants should be better able to: Discuss the clinical importance and biologic rationale for targeting HER3 and TROP2 with novel ADCs in lung cancer; Summarize the characteristics, mechanisms of action, and safety and efficacy profiles of ADCs targeting HER3 and TROP2 in NSCLC; Identify patients with NSCLC who are likely to be appropriate candidates for treatment with novel ADCs targeting HER3 and TROP2; and Implement best practices to effectively and safely integrate novel ADCs, including those targeting HER3 and TROP2, into treatment plans for appropriate patients with NSCLC

Go online to PeerView.com/YMP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Antibody–drug conjugates (ADCs) are the next frontier in the treatment of lung cancer, addressing unmet needs, expanding options, and providing new hope of improved outcomes for diverse populations of patients. Extensive efforts are ongoing to evaluate and bring new ADCs to clinical practice, including those targeting HER3 and TROP2. Initial studies have already yielded promising new data, and many other clinical trials are actively evaluating ADCs targeting HER3, TROP2, and others in different patient populations and treatment settings. This educational activity, based on a recent live symposium, provides an expert-led exploration of the fast-paced evolution of the role and impact of ADC-based approaches in lung cancer. Learners can achieve a better understanding of the structure and function of modern ADCs, the rationale for targeting HER3 and TROP2 with ADCs in lung cancer, and the rapidly accumulating evidence base supporting their use in practice. Going beyond the basics, the expert panel also shares in-depth perspectives on where the novel ADCs may fit within the complex lung cancer treatment arsenal, nuances of patient selection, how to best integrate them into treatment plans, and how to recognize and manage unique adverse events associated with different ADCs. Watch this activity to learn how to maximize the potential of these novel ADCs for the benefit of patients with lung cancer. Upon completion of this activity, participants should be better able to: Discuss the clinical importance and biologic rationale for targeting HER3 and TROP2 with novel ADCs in lung cancer; Summarize the characteristics, mechanisms of action, and safety and efficacy profiles of ADCs targeting HER3 and TROP2 in NSCLC; Identify patients with NSCLC who are likely to be appropriate candidates for treatment with novel ADCs targeting HER3 and TROP2; and Implement best practices to effectively and safely integrate novel ADCs, including those targeting HER3 and TROP2, into treatment plans for appropriate patients with NSCLC

Go online to PeerView.com/YMP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Antibody–drug conjugates (ADCs) are the next frontier in the treatment of lung cancer, addressing unmet needs, expanding options, and providing new hope of improved outcomes for diverse populations of patients. Extensive efforts are ongoing to evaluate and bring new ADCs to clinical practice, including those targeting HER3 and TROP2. Initial studies have already yielded promising new data, and many other clinical trials are actively evaluating ADCs targeting HER3, TROP2, and others in different patient populations and treatment settings. This educational activity, based on a recent live symposium, provides an expert-led exploration of the fast-paced evolution of the role and impact of ADC-based approaches in lung cancer. Learners can achieve a better understanding of the structure and function of modern ADCs, the rationale for targeting HER3 and TROP2 with ADCs in lung cancer, and the rapidly accumulating evidence base supporting their use in practice. Going beyond the basics, the expert panel also shares in-depth perspectives on where the novel ADCs may fit within the complex lung cancer treatment arsenal, nuances of patient selection, how to best integrate them into treatment plans, and how to recognize and manage unique adverse events associated with different ADCs. Watch this activity to learn how to maximize the potential of these novel ADCs for the benefit of patients with lung cancer. Upon completion of this activity, participants should be better able to: Discuss the clinical importance and biologic rationale for targeting HER3 and TROP2 with novel ADCs in lung cancer; Summarize the characteristics, mechanisms of action, and safety and efficacy profiles of ADCs targeting HER3 and TROP2 in NSCLC; Identify patients with NSCLC who are likely to be appropriate candidates for treatment with novel ADCs targeting HER3 and TROP2; and Implement best practices to effectively and safely integrate novel ADCs, including those targeting HER3 and TROP2, into treatment plans for appropriate patients with NSCLC

Go online to PeerView.com/YMP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Antibody–drug conjugates (ADCs) are the next frontier in the treatment of lung cancer, addressing unmet needs, expanding options, and providing new hope of improved outcomes for diverse populations of patients. Extensive efforts are ongoing to evaluate and bring new ADCs to clinical practice, including those targeting HER3 and TROP2. Initial studies have already yielded promising new data, and many other clinical trials are actively evaluating ADCs targeting HER3, TROP2, and others in different patient populations and treatment settings. This educational activity, based on a recent live symposium, provides an expert-led exploration of the fast-paced evolution of the role and impact of ADC-based approaches in lung cancer. Learners can achieve a better understanding of the structure and function of modern ADCs, the rationale for targeting HER3 and TROP2 with ADCs in lung cancer, and the rapidly accumulating evidence base supporting their use in practice. Going beyond the basics, the expert panel also shares in-depth perspectives on where the novel ADCs may fit within the complex lung cancer treatment arsenal, nuances of patient selection, how to best integrate them into treatment plans, and how to recognize and manage unique adverse events associated with different ADCs. Watch this activity to learn how to maximize the potential of these novel ADCs for the benefit of patients with lung cancer. Upon completion of this activity, participants should be better able to: Discuss the clinical importance and biologic rationale for targeting HER3 and TROP2 with novel ADCs in lung cancer; Summarize the characteristics, mechanisms of action, and safety and efficacy profiles of ADCs targeting HER3 and TROP2 in NSCLC; Identify patients with NSCLC who are likely to be appropriate candidates for treatment with novel ADCs targeting HER3 and TROP2; and Implement best practices to effectively and safely integrate novel ADCs, including those targeting HER3 and TROP2, into treatment plans for appropriate patients with NSCLC

Go online to PeerView.com/YMP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Antibody–drug conjugates (ADCs) are the next frontier in the treatment of lung cancer, addressing unmet needs, expanding options, and providing new hope of improved outcomes for diverse populations of patients. Extensive efforts are ongoing to evaluate and bring new ADCs to clinical practice, including those targeting HER3 and TROP2. Initial studies have already yielded promising new data, and many other clinical trials are actively evaluating ADCs targeting HER3, TROP2, and others in different patient populations and treatment settings. This educational activity, based on a recent live symposium, provides an expert-led exploration of the fast-paced evolution of the role and impact of ADC-based approaches in lung cancer. Learners can achieve a better understanding of the structure and function of modern ADCs, the rationale for targeting HER3 and TROP2 with ADCs in lung cancer, and the rapidly accumulating evidence base supporting their use in practice. Going beyond the basics, the expert panel also shares in-depth perspectives on where the novel ADCs may fit within the complex lung cancer treatment arsenal, nuances of patient selection, how to best integrate them into treatment plans, and how to recognize and manage unique adverse events associated with different ADCs. Watch this activity to learn how to maximize the potential of these novel ADCs for the benefit of patients with lung cancer. Upon completion of this activity, participants should be better able to: Discuss the clinical importance and biologic rationale for targeting HER3 and TROP2 with novel ADCs in lung cancer; Summarize the characteristics, mechanisms of action, and safety and efficacy profiles of ADCs targeting HER3 and TROP2 in NSCLC; Identify patients with NSCLC who are likely to be appropriate candidates for treatment with novel ADCs targeting HER3 and TROP2; and Implement best practices to effectively and safely integrate novel ADCs, including those targeting HER3 and TROP2, into treatment plans for appropriate patients with NSCLC

Go online to PeerView.com/YMP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Antibody–drug conjugates (ADCs) are the next frontier in the treatment of lung cancer, addressing unmet needs, expanding options, and providing new hope of improved outcomes for diverse populations of patients. Extensive efforts are ongoing to evaluate and bring new ADCs to clinical practice, including those targeting HER3 and TROP2. Initial studies have already yielded promising new data, and many other clinical trials are actively evaluating ADCs targeting HER3, TROP2, and others in different patient populations and treatment settings. This educational activity, based on a recent live symposium, provides an expert-led exploration of the fast-paced evolution of the role and impact of ADC-based approaches in lung cancer. Learners can achieve a better understanding of the structure and function of modern ADCs, the rationale for targeting HER3 and TROP2 with ADCs in lung cancer, and the rapidly accumulating evidence base supporting their use in practice. Going beyond the basics, the expert panel also shares in-depth perspectives on where the novel ADCs may fit within the complex lung cancer treatment arsenal, nuances of patient selection, how to best integrate them into treatment plans, and how to recognize and manage unique adverse events associated with different ADCs. Watch this activity to learn how to maximize the potential of these novel ADCs for the benefit of patients with lung cancer. Upon completion of this activity, participants should be better able to: Discuss the clinical importance and biologic rationale for targeting HER3 and TROP2 with novel ADCs in lung cancer; Summarize the characteristics, mechanisms of action, and safety and efficacy profiles of ADCs targeting HER3 and TROP2 in NSCLC; Identify patients with NSCLC who are likely to be appropriate candidates for treatment with novel ADCs targeting HER3 and TROP2; and Implement best practices to effectively and safely integrate novel ADCs, including those targeting HER3 and TROP2, into treatment plans for appropriate patients with NSCLC

Go online to PeerView.com/YMP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Antibody–drug conjugates (ADCs) are the next frontier in the treatment of lung cancer, addressing unmet needs, expanding options, and providing new hope of improved outcomes for diverse populations of patients. Extensive efforts are ongoing to evaluate and bring new ADCs to clinical practice, including those targeting HER3 and TROP2. Initial studies have already yielded promising new data, and many other clinical trials are actively evaluating ADCs targeting HER3, TROP2, and others in different patient populations and treatment settings. This educational activity, based on a recent live symposium, provides an expert-led exploration of the fast-paced evolution of the role and impact of ADC-based approaches in lung cancer. Learners can achieve a better understanding of the structure and function of modern ADCs, the rationale for targeting HER3 and TROP2 with ADCs in lung cancer, and the rapidly accumulating evidence base supporting their use in practice. Going beyond the basics, the expert panel also shares in-depth perspectives on where the novel ADCs may fit within the complex lung cancer treatment arsenal, nuances of patient selection, how to best integrate them into treatment plans, and how to recognize and manage unique adverse events associated with different ADCs. Watch this activity to learn how to maximize the potential of these novel ADCs for the benefit of patients with lung cancer. Upon completion of this activity, participants should be better able to: Discuss the clinical importance and biologic rationale for targeting HER3 and TROP2 with novel ADCs in lung cancer; Summarize the characteristics, mechanisms of action, and safety and efficacy profiles of ADCs targeting HER3 and TROP2 in NSCLC; Identify patients with NSCLC who are likely to be appropriate candidates for treatment with novel ADCs targeting HER3 and TROP2; and Implement best practices to effectively and safely integrate novel ADCs, including those targeting HER3 and TROP2, into treatment plans for appropriate patients with NSCLC

Thank you for listening to My Yes Is On The Table, a podcast hosted by Jennifer Hand and Coming Alive Ministries.  Today Jenn welcomes Melissa L. Johnson to talk about her new book, Soul-Deep Beauty.  Melissa is a marriage and family therapist and founder of the Impossible Beauty blog and podcast. Melissa's new book: Soul-Deep Beauty: Fighting for Our True Worth in a World Demanding Flawless Impossible Beauty podcast with Melissa Johnson Captivating podcast with Stasi Eldrege Your Next Brave Step podcast with Deb Brown Connect with Melissa L. Johnson: Instagram, Impossible-Beauty.com Connect with Jenn: Instagram, Facebook, Website DONATE to Coming Alive Ministries  

Melissa L. Johnson is a licensed marriage and family therapist, adjunct instructor at Bethel University, and the founder of Impossible Beauty, a blog and podcast dedicated to redefining beauty as “the life of God at work in us and among us”. Melissa's writing and podcast interviews seek to uncover what true beauty is, what it is not, and how we go about finding beauty in a broken world. Melissa is releasing her debut book with Bethany House publishing in June, 2023, entitled Soul-Deep Beauty: Fighting for our True Worth in a World Demanding Flawless. LISTEN TO THIS EPISODE IF: You want to learn how we are being lied to about true beauty You seek to love yourself- and others - unconditionally You want a new perspective about how true beauty invites us into an adventure and affirms our true worth You can learn more about Melissa: Instagram: @Melissa.louise.johnson Impossible Beauty Podcast www.impossible-beauty.com

On this episode of Today's Heartlift with Janell, I am joined by special guest Melissa L. Johnson, author of "Soul Deep Beauty: Fighting for Our True Worth in a World Demanding Flawless." In this bonus session, Melissa and I discuss our personal experiences with prayer and how it can shift our mindset toward a more compassionate God. Janell also shares her struggles with perfectionism and her reparative experience with Jesus. They also touch on the unrealistic beauty standards imposed by our culture and the importance of getting to know ourselves better.Learn more about Melissa and Impossible Beauty: Melissa JohnsonUse this hashtag to share your thoughts: #todaysheartliftwithjanellPlease send your questions here: janell@janellrardon.com and Text your questions and I'll answer them on the show!Meet me over on Instagram where we will share our thoughts on this week's podcast prompts: MEET ME ON INSTASo excited that the podcast has been voted in the Top 100 Mental Health Podcasts on Feedspot: https://blog.feedspot.com/mental_health_podcasts/Listen to more great podcasts: ACCESS MORE

On this episode of Today's Heartlift with Janell, I am joined by special guest Melissa L. Johnson, author of "Soul Deep Beauty: Fighting for Our True Worth in a World Demanding Flawless." In this bonus session, Melissa and I discuss our personal experiences with prayer and how it can shift our mindset toward a more compassionate God. Janell also shares her struggles with perfectionism and her reparative experience with Jesus. They also touch on the unrealistic beauty standards imposed by our culture and the importance of getting to know ourselves better.Learn more about Melissa and Impossible Beauty: Melissa JohnsonUse this hashtag to share your thoughts: #todaysheartliftwithjanellPlease send your questions here: janell@janellrardon.com and Text your questions and I'll answer them on the show!Meet me over on Instagram where we will share our thoughts on this week's podcast prompts: MEET ME ON INSTASo excited that the podcast has been voted in the Top 100 Mental Health Podcasts on Feedspot: https://blog.feedspot.com/mental_health_podcasts/Listen to more great podcasts: ACCESS MORE

Are you being sold a broken brand of beauty?Beauty narratives our culture feeds us literally destroys lives. However, God has a different version of beauty, one that's life giving, and soul deep! So let's chat it about! On this episode we welcome Melissa L. Johnson, author of Soul-Deep Beauty: Fighting for Our True Worth in a World Demanding Flawless. This conversation is so good and so necessary!Listen wherever you get your podcasts or use the link in our profile.And as always, we'd love if you'd share this episode with your friends and/or leave us a review. (Five star reviews are our faves—hint, hint, wink, wink, lol. Thank you!)About Melissa:Melissa L. Johnson (impossible-beauty.com) is a marriage and family therapist, as well as a spiritual director. She is also the founder of Impossible Beauty, a blog and podcast dedicated to redefining beauty as "the life of God at work in us and among us." Melissa lives near Minneapolis, Minnesota, with her husband.Website | Podcast | Book:https://www.impossible-beauty.comSupport the showWhat's Your Story on Instagram http://www.instagram.com/whatsyourstory.podcast To connect with Hannah visit http://www.hannahrconway.com To connect with Stephani visit http://www.stephanicook.org

Go online to PeerView.com/ANP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The treatment arsenal for NSCLC with and without genomic alterations is continuously growing, and novel HER2-, HER3-, and TROP2-targeting antibody–drug conjugates, among other agents, are showing great promise for improving outcomes in challenging subgroups of patients with lung cancer. Extensive and nuanced biomarker testing has never been more important in guiding the integration of an expanding array of current and emerging targeted therapies into practice. This PeerView Live MasterClass based on a recent live web broadcast provides evidence-based expert instruction on the evolving best practices for biomarker testing, as well as the rapidly accumulating evidence base on and clinical implications of recent advances with HER2-, HER3-, and TROP2-targeted therapies in the modern era of precision lung cancer care. Upon completion of this accredited CE activity, participants should be better able to: Review the frequency, clinical importance, and biologic rationale for targeting HER2, HER3, and TROP2 alterations with novel therapies in lung cancer, Describe the current guidelines and best practices for biomarker testing in patients with NSCLC, Summarize the characteristics, mechanisms of action, latest safety and efficacy findings, and recommendations of emerging HER2-, HER3-, and TROP2-targeted therapies in NSCLC, Integrate individualized treatment plans through different lines of therapy for patients with NSCLC that take into consideration appropriate strategies for biomarker testing/interpretation to identify patients with NSCLC who might benefit from emerging HER2-, HER3-, and TROP2-targeted therapies.

Go online to PeerView.com/ANP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The treatment arsenal for NSCLC with and without genomic alterations is continuously growing, and novel HER2-, HER3-, and TROP2-targeting antibody–drug conjugates, among other agents, are showing great promise for improving outcomes in challenging subgroups of patients with lung cancer. Extensive and nuanced biomarker testing has never been more important in guiding the integration of an expanding array of current and emerging targeted therapies into practice. This PeerView Live MasterClass based on a recent live web broadcast provides evidence-based expert instruction on the evolving best practices for biomarker testing, as well as the rapidly accumulating evidence base on and clinical implications of recent advances with HER2-, HER3-, and TROP2-targeted therapies in the modern era of precision lung cancer care. Upon completion of this accredited CE activity, participants should be better able to: Review the frequency, clinical importance, and biologic rationale for targeting HER2, HER3, and TROP2 alterations with novel therapies in lung cancer, Describe the current guidelines and best practices for biomarker testing in patients with NSCLC, Summarize the characteristics, mechanisms of action, latest safety and efficacy findings, and recommendations of emerging HER2-, HER3-, and TROP2-targeted therapies in NSCLC, Integrate individualized treatment plans through different lines of therapy for patients with NSCLC that take into consideration appropriate strategies for biomarker testing/interpretation to identify patients with NSCLC who might benefit from emerging HER2-, HER3-, and TROP2-targeted therapies.

Go online to PeerView.com/ANP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The treatment arsenal for NSCLC with and without genomic alterations is continuously growing, and novel HER2-, HER3-, and TROP2-targeting antibody–drug conjugates, among other agents, are showing great promise for improving outcomes in challenging subgroups of patients with lung cancer. Extensive and nuanced biomarker testing has never been more important in guiding the integration of an expanding array of current and emerging targeted therapies into practice. This PeerView Live MasterClass based on a recent live web broadcast provides evidence-based expert instruction on the evolving best practices for biomarker testing, as well as the rapidly accumulating evidence base on and clinical implications of recent advances with HER2-, HER3-, and TROP2-targeted therapies in the modern era of precision lung cancer care. Upon completion of this accredited CE activity, participants should be better able to: Review the frequency, clinical importance, and biologic rationale for targeting HER2, HER3, and TROP2 alterations with novel therapies in lung cancer, Describe the current guidelines and best practices for biomarker testing in patients with NSCLC, Summarize the characteristics, mechanisms of action, latest safety and efficacy findings, and recommendations of emerging HER2-, HER3-, and TROP2-targeted therapies in NSCLC, Integrate individualized treatment plans through different lines of therapy for patients with NSCLC that take into consideration appropriate strategies for biomarker testing/interpretation to identify patients with NSCLC who might benefit from emerging HER2-, HER3-, and TROP2-targeted therapies.

Go online to PeerView.com/ANP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The treatment arsenal for NSCLC with and without genomic alterations is continuously growing, and novel HER2-, HER3-, and TROP2-targeting antibody–drug conjugates, among other agents, are showing great promise for improving outcomes in challenging subgroups of patients with lung cancer. Extensive and nuanced biomarker testing has never been more important in guiding the integration of an expanding array of current and emerging targeted therapies into practice. This PeerView Live MasterClass based on a recent live web broadcast provides evidence-based expert instruction on the evolving best practices for biomarker testing, as well as the rapidly accumulating evidence base on and clinical implications of recent advances with HER2-, HER3-, and TROP2-targeted therapies in the modern era of precision lung cancer care. Upon completion of this accredited CE activity, participants should be better able to: Review the frequency, clinical importance, and biologic rationale for targeting HER2, HER3, and TROP2 alterations with novel therapies in lung cancer, Describe the current guidelines and best practices for biomarker testing in patients with NSCLC, Summarize the characteristics, mechanisms of action, latest safety and efficacy findings, and recommendations of emerging HER2-, HER3-, and TROP2-targeted therapies in NSCLC, Integrate individualized treatment plans through different lines of therapy for patients with NSCLC that take into consideration appropriate strategies for biomarker testing/interpretation to identify patients with NSCLC who might benefit from emerging HER2-, HER3-, and TROP2-targeted therapies.

Go online to PeerView.com/ANP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The treatment arsenal for NSCLC with and without genomic alterations is continuously growing, and novel HER2-, HER3-, and TROP2-targeting antibody–drug conjugates, among other agents, are showing great promise for improving outcomes in challenging subgroups of patients with lung cancer. Extensive and nuanced biomarker testing has never been more important in guiding the integration of an expanding array of current and emerging targeted therapies into practice. This PeerView Live MasterClass based on a recent live web broadcast provides evidence-based expert instruction on the evolving best practices for biomarker testing, as well as the rapidly accumulating evidence base on and clinical implications of recent advances with HER2-, HER3-, and TROP2-targeted therapies in the modern era of precision lung cancer care. Upon completion of this accredited CE activity, participants should be better able to: Review the frequency, clinical importance, and biologic rationale for targeting HER2, HER3, and TROP2 alterations with novel therapies in lung cancer, Describe the current guidelines and best practices for biomarker testing in patients with NSCLC, Summarize the characteristics, mechanisms of action, latest safety and efficacy findings, and recommendations of emerging HER2-, HER3-, and TROP2-targeted therapies in NSCLC, Integrate individualized treatment plans through different lines of therapy for patients with NSCLC that take into consideration appropriate strategies for biomarker testing/interpretation to identify patients with NSCLC who might benefit from emerging HER2-, HER3-, and TROP2-targeted therapies.

Go online to PeerView.com/ANP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The treatment arsenal for NSCLC with and without genomic alterations is continuously growing, and novel HER2-, HER3-, and TROP2-targeting antibody–drug conjugates, among other agents, are showing great promise for improving outcomes in challenging subgroups of patients with lung cancer. Extensive and nuanced biomarker testing has never been more important in guiding the integration of an expanding array of current and emerging targeted therapies into practice. This PeerView Live MasterClass based on a recent live web broadcast provides evidence-based expert instruction on the evolving best practices for biomarker testing, as well as the rapidly accumulating evidence base on and clinical implications of recent advances with HER2-, HER3-, and TROP2-targeted therapies in the modern era of precision lung cancer care. Upon completion of this accredited CE activity, participants should be better able to: Review the frequency, clinical importance, and biologic rationale for targeting HER2, HER3, and TROP2 alterations with novel therapies in lung cancer, Describe the current guidelines and best practices for biomarker testing in patients with NSCLC, Summarize the characteristics, mechanisms of action, latest safety and efficacy findings, and recommendations of emerging HER2-, HER3-, and TROP2-targeted therapies in NSCLC, Integrate individualized treatment plans through different lines of therapy for patients with NSCLC that take into consideration appropriate strategies for biomarker testing/interpretation to identify patients with NSCLC who might benefit from emerging HER2-, HER3-, and TROP2-targeted therapies.

Go online to PeerView.com/ANP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The treatment arsenal for NSCLC with and without genomic alterations is continuously growing, and novel HER2-, HER3-, and TROP2-targeting antibody–drug conjugates, among other agents, are showing great promise for improving outcomes in challenging subgroups of patients with lung cancer. Extensive and nuanced biomarker testing has never been more important in guiding the integration of an expanding array of current and emerging targeted therapies into practice. This PeerView Live MasterClass based on a recent live web broadcast provides evidence-based expert instruction on the evolving best practices for biomarker testing, as well as the rapidly accumulating evidence base on and clinical implications of recent advances with HER2-, HER3-, and TROP2-targeted therapies in the modern era of precision lung cancer care. Upon completion of this accredited CE activity, participants should be better able to: Review the frequency, clinical importance, and biologic rationale for targeting HER2, HER3, and TROP2 alterations with novel therapies in lung cancer, Describe the current guidelines and best practices for biomarker testing in patients with NSCLC, Summarize the characteristics, mechanisms of action, latest safety and efficacy findings, and recommendations of emerging HER2-, HER3-, and TROP2-targeted therapies in NSCLC, Integrate individualized treatment plans through different lines of therapy for patients with NSCLC that take into consideration appropriate strategies for biomarker testing/interpretation to identify patients with NSCLC who might benefit from emerging HER2-, HER3-, and TROP2-targeted therapies.

Go online to PeerView.com/ANP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The treatment arsenal for NSCLC with and without genomic alterations is continuously growing, and novel HER2-, HER3-, and TROP2-targeting antibody–drug conjugates, among other agents, are showing great promise for improving outcomes in challenging subgroups of patients with lung cancer. Extensive and nuanced biomarker testing has never been more important in guiding the integration of an expanding array of current and emerging targeted therapies into practice. This PeerView Live MasterClass based on a recent live web broadcast provides evidence-based expert instruction on the evolving best practices for biomarker testing, as well as the rapidly accumulating evidence base on and clinical implications of recent advances with HER2-, HER3-, and TROP2-targeted therapies in the modern era of precision lung cancer care. Upon completion of this accredited CE activity, participants should be better able to: Review the frequency, clinical importance, and biologic rationale for targeting HER2, HER3, and TROP2 alterations with novel therapies in lung cancer, Describe the current guidelines and best practices for biomarker testing in patients with NSCLC, Summarize the characteristics, mechanisms of action, latest safety and efficacy findings, and recommendations of emerging HER2-, HER3-, and TROP2-targeted therapies in NSCLC, Integrate individualized treatment plans through different lines of therapy for patients with NSCLC that take into consideration appropriate strategies for biomarker testing/interpretation to identify patients with NSCLC who might benefit from emerging HER2-, HER3-, and TROP2-targeted therapies.